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ABSTRACT 
Obesity is a global health problem and affects women of reproductive age. 
During pregnancy, obesity increases the risk for gestational diabetes mellitus 
(GDM), in turn predisposing for type 2 diabetes (T2D). Not only the amount and 
distribution of adipose tissue (AT) but also the AT morphology and function are 
of importance in pathogenesis of metabolic disease related to obesity. The aims 
of this thesis were 1) to compare subcutaneous (SC) and visceral AT regarding 
release of adipokines, implicated in insulin resistance/inflammation, using an in 
vitro system reflecting the release in vivo, and 2) to characterize AT morphology 
and function in normal weight (NW) and obese pregnant women in trimester 1 
and 3, and in women with previous GDM, and identify AT-related factors 
associated with insulin resistance and impaired glucose metabolism.  
AT biopsies were obtained from 1) patients undergoing surgery at Sahlgrenska 
University Hospital, and 2) women in the Pregnancy Obesity Nutrition and Child 
Health (PONCH) study. AT adipokine release and immune cell/blood vessel 
density, and adipocyte size/number and lipolytic activity were analyzed. Women 
were examined regarding insulin resistance (HOMA-IR), glucose tolerance, 
body composition and blood chemistry. 
Chemerin, cytokines, and dipeptidyl peptidase 4 were more abundantly released 
from visceral than SC AT; adiponectin release was higher from the SC depot. 
During pregnancy, NW women accumulated fat in existing adipocytes (which 
became larger) and adiponectin levels were reduced. Obese women had signs of 
adipocyte recruitment and maintained adiponectin levels. Fat mass and the 
proportion of very large adipocytes were associated with HOMA-IR in trimester 
3. In women with previous GDM, follow-up body mass index (BMI) was the 
best discriminator of normal vs impaired glucose metabolism, and waist-to-
height ratio and adipocyte volume were associated with HOMA-IR. 
To conclude, adipokines implicated in metabolic dysfunction are released from 
AT in a depot-dependent manner. AT mass/morphology contribute to gestational 
insulin resistance. During pregnancy, AT morphology appears to change 
oppositely in NW and obese women, possibly protecting obese women against 
even more severe insulin resistance. To prevent T2D, BMI and abdominal fat 
accumulation should be controlled in women after GDM. 
Keywords: Adipose tissue, adipocyte, adipokines, insulin resistance, 
pregnancy, gestational diabetes mellitus, type 2 diabetes mellitus  
 
   
SAMMANFATTNING PÅ SVENSKA 
Bilden av fettväven som ett passivt organ för lagring av energi har ändrats 
drastiskt. Idag anses fettväven vara ett dynamiskt och viktigt organ, 
involverat i många biologiska processer i kroppen. Fettväven producerar och 
frisätter bl. a. ett stort antal bioaktiva ämnen, adipokiner, som påverkar 
aptitreglering, inflammation och insulinkänslighet. Förekomst av övervikt 
och fetma har ökat världen över och i fetmaepidemins spår följer metabola 
sjukdomar som diabetes typ 2 och hjärt-kärlsjukdom. Även kvinnor i 
reproduktiv ålder har blivit fetare. Fetma under graviditet kan leda till 
komplikationer som graviditetsdiabetes vilket i sin tur innebär en ökad risk 
för kvinnan att senare insjukna i diabetes typ 2. Fettvävens roll i utveckling 
av följdsjukdomar till fetma är inte helt klarlagd men det står klart att inte 
bara mängden fett, och dess placering på kroppen, utan även dess morfologi 
och funktion är av betydelse. 
Syftet med denna avhandling var 1) att jämföra subkutan (under huden) och 
visceral (inne i bukhålan) fettväv med avseende på frisättning av några 
adipokiner, relaterade till fetma och metabola störningar, med hjälp av ett in 
vitro system som återspeglar frisättningen in vivo, och 2) att studera 
fettvävens morfologi och funktion hos normalviktiga och feta kvinnor 
longitudinellt under graviditet, och hos kvinnor som tidigare utvecklat 
graviditetsdiabetes, samt att identifiera fettvävsrelaterade faktorer med 
betydelse för utveckling av insulinresistens och försämrad 
glukosmetabolism. 
Fettvävsbiopsier samlades från 1) patienter som opererades vid Sahlgrenska 
Universitetsjukhuset, och 2) kvinnor i den så kallade PONCH (Pregnancy 
Obesity Nutrition and Child Health)-studien. Fettvävens frisättning av 
adipokiner och innehåll av immunceller och blodkärl, samt fettcellernas 
storlek/antal och lipolytiska aktivitet analyserades. Kvinnorna undersöktes 
avseende insulinresistens (HOMA-IR), glukostolerans, 
kroppssammansättning och blodkemi. 
Adipokiner såsom chemerin, cytokiner och dipeptidylpeptidas 4 frisattes i 
större omfattning från den viscerala fettväven medan frisättning av 
adiponectin var högst i subkutan fettväv. Under graviditet fylldes fett på i 
redan befintliga fettceller hos normalviktiga kvinnor (fettcellerna blev i snitt 
större) och deras adiponectin-nivåer sjönk. I jämförelse med den 
normalviktiga gruppen visade feta kvinnor tecken till nyrekrytering av 
fettceller (fettcellerna blev i snitt mindre) och deras adiponectin-nivåer 
bibehölls. Fettmassa och andelen mycket stora fettceller var associerade till 
HOMA-IR sent i graviditeten. Hos kvinnor med tidigare GDM var 
kroppsmasseindex (BMI) vid uppföljningen den faktor som var starkast 
associerad till försämrad glukosmetabolism, medan kvinnornas midja-längd-
kvot och fettcellsvolym var starkast associerade till HOMA-IR. 
  
Sammantaget visar dessa studier att flera adipokiner som är relaterade till 
fetma och metabola störningar har en depå-beroende frisättning från 
människans fettväv. Den viscerala fettvävens frisättningsmönster är mer 
ogynnsamt ur metabol synvinkel. Fettvävens massa och morfologi bidrar till 
den fysiologiskt förhöjda insulinresistens som uppstår under graviditet. 
Under graviditet tycks fettvävens morfologi förändras på motsatt sätt hos 
normalviktiga och feta kvinnor – andelen små fettceller ökar hos feta kvinnor 
medan andelen stora fettceller ökar hos normalviktiga kvinnor. Rekrytering 
av fettceller under graviditet kan, hypotetiskt, skydda feta kvinnor från än 
mer uttalad insulinresistens. För att förebygga diabetes typ 2 bör kvinnor 
efter GDM få information om sin förhöjda diabetesrisk och, vid behov, stöd 
för viktnedgång. 
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1 BACKGROUND 
Adipose tissue is an organ for storage of energy and has the ability to expand 
in response to overnutrition and release lipids in response to energy deficit. 
However, adipose tissue is far more than a caloric reservoir, it is also a key 
component in maintaining metabolic homeostasis and is involved in a wide 
array of biological processes throughout the body. It has been proposed that 
the lifestyle of the modern human is detrimental for our health. Easy access 
to energy-rich food, combined with a sedentary lifestyle has led to obesity 
becoming the most common nutritional disorder worldwide. In its trail comes 
increasing numbers of people suffering from co-morbidities associated with 
obesity, such as diabetes, cardiovascular disease and certain cancers. The 
World Health Organization (WHO) calls this global increase in prevalence of 
overweight and obesity “globesity”. 
1.1 Obesity 
In recent years the prevalence of obesity has been said to reach epidemic 
proportions and the WHO has made it one of their global targets to halt the 
rise in diabetes and obesity. Overweight and obesity is defined by body mass 
index (BMI), calculated by dividing body weight (in kilograms) by the 
square of body height (in meters). Having a BMI equal to or more than 25 
kg/m2 is defined as overweight and BMI of 30 kg/m2 or more is defined as 
obesity. Obesity has more than doubled since 1980 and the most recent data 
from WHO (2014) shows that rates of obesity and overweight have 
continued to increase in all countries around the world. In 2014, 39% of 
adults were overweight and 13% were obese worldwide. In Sweden both 
overweight and obesity have increased between 2010 and 2014 according to 
data from WHO, Fig 1(1). 
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Figure 1. Prevalence of overweight and obesity in men and women in Sweden 2010 
and 2014. Data from WHO global status report on non-communicable diseases 
2014.   
Overweight and obesity are associated with a profound health burden and 
have been identified as major risk factors for developing co-morbidities 
including hypertension, type 2 diabetes mellitus (T2D), cardiovascular 
disease and certain cancers (2, 3). Also, in parallel to increasing numbers of 
obesity, there is an increase in the prevalence of T2D, although somewhat 
delayed, and the majority of people with T2D are overweight or obese (4). 
1.2 Obesity in pregnancy 
As obesity has increased in the adult population at large, it has also increased 
in women of reproductive age. More women than ever before are entering 
pregnancy overweight or obese and maternal obesity is becoming an 
increasing public health issue (5). Obesity during pregnancy is associated 
with adverse outcomes for the mother as well for the child during pregnancy, 
at delivery and after delivery. Also, obesity negatively affects fertility (6). 
During pregnancy, maternal complications related to obesity include 
increased risk for developing hypertension and pre-eclampsia (7, 8), 
thromboembolism (9) and gestational diabetes mellitus (GDM) (7, 9, 10).  
Several reviews have shown an association between obesity and the risk of 
developing GDM and obese women are at least four times more likely to 
develop GDM compared to normal weight pregnant women. The risk is even 
higher with severe obesity (11, 12).  
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Maternal obesity in pregnancy is also associated with increased risk for 
complications during parturition. The rate of instrumental deliveries and 
caesarian section is higher in obese mothers (7, 8). This increased risk is 
likely multifactorial and may be due to sub-optimal uterine contractions 
resulting in prolonged and ineffective labor or fat deposition in the pelvic 
area resulting in a narrow birth canal. In addition to this, maternal obesity 
increases the likelihood of giving birth to a child, large for gestational age, 
that may further aggravate the situation (13).  
It has been suggested that increased glucose concentrations in maternal 
obesity or GDM lead to increased fetal growth (14, 15) and macrosomic 
babies (7, 9, 16) with increased risk for neonatal hypoglycemia and need for 
neonatal intensive care after birth (16, 17). 
1.3 Insulin resistance and diabetes mellitus 
In the recent decades there has been an increase in the prevalence of T2D 
globally and in low and middle-income countries the incidence rate of T2D is 
particularly high (1). Overweight, obesity and lack of physical activity are 
factors that have been attributed to drive the increase in T2D (18).  
Diabetes is a chronic disease, resulting from insufficient insulin production 
by the pancreas, ineffective response to insulin stimulation in target tissues or 
both. Type 1 diabetes mellitus results from insufficient insulin production 
and requires lifelong substitution with insulin whereas T2D, which accounts 
for 90% of all cases of diabetes, is largely due to physical inactivity and 
excess body weight, although there are genetic components (19). T2D is 
characterized by ineffective use of insulin in the liver, skeletal muscles and 
adipose tissue. The insulin-producing β-cells of the pancreas compensate for 
the increased resistance to the actions of insulin by producing more insulin, 
leading to increased circulating insulin levels as well as progressively 
increasing glucose levels (20). Glucose levels in T2D are maintained by 
lifestyle changes, drugs that improve insulin sensitivity, lower glucose 
production by the liver, or stimulate the pancreas to produce more insulin. 
Eventually, the β-cells fail to maintain the high circulating insulin levels 
required and insulin must be substituted as in type 1 diabetes. Poor glycemic 
control accelerates development of complications associated with diabetes 
including cardiovascular disease, retinopathy, nephropathy and neuropathy.  
Human adipose tissue morphology and function 
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1.3.1 Gestational diabetes mellitus 
The prevalence of women diagnosed with diabetes during pregnancy has 
increased globally (21, 22). There are ethnical differences in incidence and 
there is no consensus regarding criteria used for diagnosis resulting in 1-18% 
prevalence in GDM worldwide (23). Beside ethnicity and obesity as risk 
factors for GDM, also GDM in previous pregnancies, advancing maternal 
age, and low socioeconomic status have been identified as risk factors for 
developing GDM (24, 25). Although the pathologic glucose resistance in 
GDM usually resolves following parturition, a pregnancy complicated by 
GDM predicts a high risk for developing T2D later in life (26, 27). 
Progression rate from GDM to T2D varies due to the length of the follow-up 
and diagnostic criteria, but as reviewed by Bellamy et al, there is at least a 
seven-fold increased risk for progression to T2D in women with previous 
GDM (27).   
1.3.2 Diagnostic criteria 
 Diagnostic criteria for diabetes is based on circulating glucose levels, 
random in non-fasted state, in fasted state or during a 75g oral glucose 
tolerance test (OGTT), see Table 1. With the use of fasting plasma glucose 
and/or OGTT, the prediabetic states impaired fasting glucose (IFG) and 
impaired glucose tolerance (IGT) may be detected. IFG is thought to develop 
due to reduced hepatic insulin sensitivity combined with a stationary β-cell 
dysfunction, whereas in IGT insulin sensitivity is decreased in peripheral 
tissues and there is a progressive loss of β-cell function. Hepatic insulin 
sensitivity may not be affected in this case. In combined forms of IFG and 
IGT there are defects in both peripheral and hepatic insulin sensitivity (28). 
Table 1. WHO criteria for diagnosis of diabetes, IGT and IFG 
Normal  
Fasting plasma glucose 
and 
OGTT 2-h plasma glucose 
<6.1 mmol/l 
and 
<7.8 mmol/l 
Diabetes  
Fasting plasma glucose 
or 
OGTT 2-h plasma glucose 
≥7.0 mmol/l 
or 
≥11.1 mmol/l 
Impaired Glucose Tolerance (IGT)  
Fasting plasma glucose 
and 
OGTT 2-h plasma glucose 
<7.0 mmol/l 
and 
≥7.8 and <11.1 mmol/l 
Impaired Fasting Glucose (IFG)  
Fasting plasma glucose 
and (if measured) 
2-h plasma glucose 
≥6.1 mmol/l and ≤6.9 mmol/l 
and 
<7.8 mmol/l 
Henrik Svensson 
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1.4 Adipose tissue 
White adipose tissue is comprised of two principal components; tightly 
packed spherical adipocytes (29) and the stromal vascular fraction consisting 
mainly of preadipocytes, immune cells and fibroblasts. Endothelial cells and 
pericytes are also present, forming a network of capillaries and lymphatic 
vessels (30). Together adipocytes and cells of the stromal vascular fraction 
produce an extracellular matrix to maintain the structural and functional 
integrity of the tissue (31). 
Adipose tissue was for long regarded as an inert and passive organ with the 
sole purposes to store energy and serve as insulation. Beginning with the 
discovery that leptin is secreted from adipocytes in 1994 this view has 
changed dramatically. Nowadays adipose tissue is considered to be an 
important and active organ for maintenance of systemic homeostasis through 
an intricate network of auto-, para- and endocrine crosstalk to other tissues 
and organs (32). Since the discovery of leptin, a large number of bioactive 
molecules, produced and secreted from adipose tissue have been identified, 
collectively named adipokines and still, novel adipokines and their roles in 
health and disease are proposed (33-35).  
Although obesity and fat mass expansion is closely linked to adverse 
metabolic consequences, not all obese individuals develop insulin resistance 
and subsequently T2D. The concepts of the metabolically healthy obese and 
the opposite, the metabolically obese, normal weight individual, suggests that 
not only the quantity, but rather the quality and localization of the fat are 
important factors in the pathogenesis of co-morbidities connected to obesity 
(36, 37). 
1.4.1 Adipose tissue in pregnancy 
During pregnancy adipose tissue must expand rapidly to meet the needs of 
the growing fetus and to prepare for lactation. Maternal body fat mass 
increases from the first trimester and throughout pregnancy (38) and in 
healthy pregnancy most of the fat is stored subcutaneously on the trunk (39). 
Obesity during pregnancy further increases the progressive insulin resistance 
seen in pregnancy (40) and it has been proposed that inability of adipose 
tissue to expand properly during pregnancy is associated with development 
of GDM (41). Also, changes in lipolytic activity occurs during pregnancy in 
order to promote fat accumulation early in pregnancy, and to enhance fat 
mobilization late in pregnancy (42). 
Human adipose tissue morphology and function 
6 
1.4.2 Regional adipose tissue distribution 
The distribution of white adipose tissue may largely be divided into two 
compartments or depots; subcutaneous adipose tissue and visceral adipose 
tissue. Visceral adipose tissue is mainly located in the abdominal cavity and 
mediastinum, surrounding the inner organs, while subcutaneous adipose 
tissue forms a layer under the skin. Visceral adipose tissue can be further 
divided into depots depending on localization with omental fat superficially 
surrounding the intestines, mesenteric fat located more deeply around the 
intestines and retroperitoneal fat surrounding the kidneys. There are also 
smaller amounts of fat located in the mediastinum, surrounding the heart and 
larger vessels (29, 43). In pathological states fat may also accumulate in 
tissues and organs other than adipose tissue, thus forming ectopic fat. This 
can be seen in the liver, pancreas and skeletal muscle, leading to impaired 
function of the tissue or organ (44). 
Central and peripheral adiposity 
Vague postulated in the mid 20th century that obesity is not a homogenous 
condition and that regional distribution of adipose tissue is of importance in 
understanding metabolic disturbances linked to obesity (45). Since then 
several studies have shown that central adiposity, where fat is mainly located 
abdominally (apple-shape or android adiposity) is associated with higher risk 
for development of insulin resistance, T2D and cardio-vascular disease as 
opposed to having a more peripheral distribution of adipose tissue, in the 
lower body (pear-shaped or gynoid adiposity) which may be protective 
against T2D (46-51). 
To assess visceral adiposity directly, imaging techniques such as computed 
tomography or magnetic resonance imaging must be used, as anthropometric 
measurements are unable to distinguish subcutaneous from visceral 
abdominal fat.  However, calculating waist-to-hip ratio (WHR) from waist- 
and hip circumferences can be used as an index of abdominal fat 
accumulation. WHR has been shown to be a predictor of T2D (48, 52). 
Waist-to-height ratio is another surrogate measure of abdominal adiposity 
that has been suggested to be a better predictor of T2D than WHR or waist 
circumference alone (53-55). 
1.4.3 Adipose tissue depot-specific differences 
There are phenotypic differences between various adipose tissue depots. In 
recent years the interest of the physiology and the role of visceral adipose 
tissue in obesity-related pathology has increased. Visceral adipose tissue is 
more metabolically active than subcutaneous adipose tissue and the basal 
Henrik Svensson 
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lipolytic rate is higher in adipocytes isolated from omental and mesenteric 
adipose tissue compared to subcutaneous adipose tissue (56, 57). 
Catecholamine-induced lipolytic activity is stronger while the anti-lipolytic 
effect of insulin is weaker in visceral fat compared to subcutaneous fat (57-
59).  
Visceral adipose tissue has been proposed to have a specific secretory 
profile, with higher expression and secretion of pro-inflammatory cytokines 
and lower secretion of anti-inflammatory adipokines (60, 61). Visceral 
adipose tissue is drained by the portal venous system and is thus directly 
connected to the liver. In the portal hypothesis, it has been suggested that due 
to the high lipid turnover and secretory profile of visceral adipose tissue in 
combination with the vascular anatomy, having excess visceral fat results in 
increased concentrations of free fatty acids and pro-inflammatory cytokines 
in the portal circulation. This in turn, can impair insulin response in the liver 
(62, 63) and increase hepatic production of lipoproteins and glucose, 
promoting dyslipidemia, glucose intolerance and hyperinsulinemia (64). 
Infusion of free fatty acids in humans induced both peripheral and hepatic 
insulin resistance, supporting this theory (65, 66). 
1.5 Adipocytes 
The majority of the volume of mature white adipocytes is occupied by a 
centrally positioned, unilocular lipid droplet. The sparse cytoplasm, cup-
shaped nucleus and other organelles are displaced to the periphery of the cell 
(67). The adipocyte is remarkably flexible in terms of energy storage. 
Adipocyte size varies depending on the balance between mobilization 
(lipolysis) of triglycerides to fatty acids released to fuel peripheral tissues 
upon metabolic demand, and uptake of fatty acids, esterification and storage 
of triglyceride in response to insulin stimulation, during positive energy 
balance.  
The volume of adipocytes can vary several thousand-fold, in relation to the 
amount of lipid stored in the cell. The size of adipocytes within the adipose 
tissue is an important factor of the overall function of the tissue (68). 
Increased adipocyte size has been associated with insulin resistance, T2D and 
dyslipidemia (50, 68-70) and large abdominal adipocytes have been 
identified as being an independent predictor of T2D (55, 71). 
Human adipose tissue morphology and function 
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1.5.1 Functional differences between small and 
large adipocytes 
Enlarged adipocytes have higher glucose metabolism and increased lipid 
mobilization than smaller cells and in vitro studies have shown that large 
adipocytes are less sensitive to the stimulating actions of insulin on glucose 
metabolism (72-74). Following insulin stimulation of adipocytes, small 
adipocytes doubled the amount of GLUT4 glucose transporter in the plasma 
membrane, whereas in large adipocytes the amount of GLUT4 was 
unchanged (74). Increasing cell size alters adipokine expression and release-
patterns of adipocytes with increased release of pro-inflammatory cytokines 
and leptin in large adipocytes (75, 76) while release of the insulin-sensitizing 
adipokine adiponectin is negatively associated with adipocyte size (77, 78), 
together contributing to a pro-inflammatory environment in the tissue as well 
as systemically. Also, large adipocytes have higher release of immune cell 
chemoattractant substances (75). In reduction of adipocyte size during weight 
loss, adipokine release patterns are restored (79-81), macrophage density is 
reduced (82) and whole-body insulin sensitivity is improved (81).  
1.5.2 Adipose tissue expansion 
In excess caloric intake, preexisting adipocytes can increase in volume 
(hypertrophy) or new adipocytes can be generated from preadipocytes 
(hyperplasia), or a combination of both (83) coupled with remodeling of the 
extra cellular matrix. 
Adipocyte number is said to remain rather constant in adults suggesting 
primarily hypertrophy to occur in adults, but adipocyte turnover occurs at all 
ages, both in lean and obese subjects (84). Short term overfeeding in humans 
has been shown to lead to increased adipocyte size in lean subjects (85, 86) 
whereas obese subjects showed increased number of adipocytes with weight 
gain (50). Recruitment of new adipocytes has also been found to occur when 
women with large adipocytes were put on a high calorie diet but this was not 
seen in men, regardless of baseline adipocyte size (86). Recruitment of 
adipocytes has also been reported during pregnancy in normal weight women 
when gluteal adipose tissue was studied (87). It is possible that body fat mass 
expansion is associated with an initial increase in adipocyte size but when 
adipocytes reach a storage threshold, further expansion require an increase in 
the number of adipocytes, but this remains to be elucidated (88). Expansion 
and remodeling of adipose tissue is necessary for preventing ectopic 
deposition of fat in other tissues and organs leading to development of 
insulin resistance (89, 90). 
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1.6 Stromal vascular fraction 
The stromal vascular fraction of adipose tissue consists mainly of 
preadipocytes, fibroblasts, endothelial cells, blood and lymphatic vessels and 
infiltrating immune cells (30). A majority of proinflammatory cytokines 
released from adipose tissue originates from the non-fat cells, (91). 
Infiltration and accumulation of immune cells in adipose tissue during tissue-
expansion has been suggested to connect obesity to the chronic low-grade 
inflammation seen in obesity, insulin resistance and T2D. 
1.6.1 Macrophages 
In 2003 Weisberg et al (92) and Xu et al (93) studied gene expression-
patterns in lean and obese mice and found differences in expression of genes 
related to macrophages. Morphologic studies confirmed an increased number 
of macrophages in adipose tissue of obese mice. Since then, adipose tissue 
accumulation of macrophages in obesity has also been shown in humans 
(92), however results are not as robust in humans as in rodents (82, 94, 95). 
Macrophage-accumulation in human obesity is more pronounced in visceral 
than subcutaneous adipose tissue (95, 96). Also, adipose tissue of lean 
individuals contains tissue resident macrophages, however there are 
phenotypic differences between the macrophages seen in lean and obese 
adipose tissue. In lean individuals, macrophages are mainly involved in 
tissue repair and have been identified as M2, or alternatively activated 
macrophages. In obese adipose tissue on the other hand, recruited 
macrophages are involved in inflammatory processes, secrete pro-
inflammatory cytokines, and have been identified as M1 or classically 
activated macrophages (97). Macrophages can impact adipose tissue function 
by secretion of TNF-α, which in turn acts locally in the tissue inducing 
production of proinflammatory cytokines in adipocytes, leading to 
dysregulated basal lipolysis. The fatty acids released from adipocytes can 
activate macrophages via toll like receptors and thus, this viscous circle of 
cellular cross-talk aggravates and maintains the chronic low-grade 
inflammation (98). Weight loss decreases macrophage density and improves 
glucose sensitivity (82) and the remaining macrophages undergo a 
phenotypic shift with reduced expression of inflammatory genes and induced 
expression of the anti-inflammatory cytokine IL-10 (82, 99).  
1.6.2 Mast cells 
The functional role of mast cells in allergy is well known, however, mast 
cells may also have a role in development and maintenance of chronic 
inflammation (100). Increased mast cell density in adipose tissue has been 
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reported in diet induced obese mice (101, 102) and human subcutaneous 
adipose tissue of obese individuals (101). Infiltration of mast cells in adipose 
tissue has been proposed to precede macrophage infiltration, supported by 
the finding that mice, deficient in mature mast cells gained less weight and 
showed less macrophage infiltration when put on a high fat diet (103). Also, 
pharmacological inhibition of mast cell degranulation in mice showed similar 
results (101). Structurally, human adipose tissue mast cells have been located 
preferentially in fibrous areas of the tissue and there is a positive correlation 
between mast cell density and macrophage density in adipose tissue (104). 
1.6.3 Vascularization of adipose tissue 
A dense network of capillaries provides delivery of oxygen and nutrients to 
the tissue but also provides a route for secreted adipokines to reach other 
tissues and organs (105). Subcutaneous adipose tissue is more densely 
vascularized than visceral adipose tissue (106). During positive energy 
balance and adipose tissue expansion, angiogenesis is enhanced to provide 
adequate nutritional supply (107) but in obesity and insulin resistance 
decreased capillary density has been observed parallel to an increase in the 
number of larger vessels in adipose tissue (108). 
In adipose tissue expansion, the interstitial oxygen tension decreases as 
adipocytes become enlarged, creating areas of local hypoxia (33). If 
neovascularization fails or is not rapid enough, increased hypoxia and cell 
death occurs, leading to an influx of macrophages and other immune cells, 
which in turn increases the inflammatory state of the tissue (109). 
1.7 Adipokines 
In the early 1990’s Zhang et al identified leptin as a secreted product from 
adipose tissue and this discovery led to a paradigm-shift in obesity research 
(110). Around the same time of the discovery of leptin, Hotamisligil et al 
reported increased mRNA expression of TNF-α in obese adipose tissue, 
which was identified as a negative regulator of insulin signaling and 
proposing obesity to be a state of chronic low-grade inflammation (111). 
These findings provided a foundation for the subsequent discovery of many 
other adipokines and established adipose tissue as a dynamic and active 
secretory organ.  
Adipokines, secreted from adipose tissue, are involved in a wide spectrum of 
biological processes, including regulation of energy homeostasis (satiety, 
appetite, lipid- and carbohydrate metabolism), adipocyte proliferation and 
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differentiation, inflammation, angiogenesis and regulation of coagulation and 
vascular function (33, 112, 113). Adipokines can act locally in adipose tissue 
(auto- and paracrine manners), but can also exert their effect in distant organs 
and tissues through the systemic circulation (endocrine manner). Some 
adipokines are adipocyte specific, such as leptin and adiponectin, while 
others, like proinflammatory cytokines, to a higher degree are secreted from 
the non-fat cells in adipose tissue (114). In obesity, dysregulation of pro- and 
anti-inflammatory cytokines released from adipose tissue drive the chronic 
low-grade systemic inflammation thereby contributing to development of 
metabolic and cardiovascular disorders (30, 115). 
Adipokines are secreted through different mechanisms. Adiponectin and 
leptin are examples of adipokines secreted through the classical pathway, 
dependent of the endoplasmic reticulum and golgi apparatus. Other 
adipokines, like dipeptidyl peptidase 4 (DPP4) and TNF-α, are released from 
the adipocytes by proteolytic cleavage and shedding from the plasma 
membrane, releasing the soluble form of the adipokine. Release of 
adipokines may be constitutive, regulated or a combination of both. Further, 
the secretory mechanisms of several adipokines are still unknown (116).  
1.7.1 Leptin 
Leptin is mainly produced by adipocytes and is a multifunctional adipokine 
with widespread effects in the body, regulating food intake, energy 
expenditure and is also involved in angiogenesis and wound healing (117). 
Plasma levels of leptin increase with weight gain and decrease with weight 
loss (118). There is a positive linear correlation between circulating levels of 
leptin and total body fat mass and there is an increased release of leptin from 
large compared with small adipocytes (119). When leptin levels are 
decreased, appetite is increased and energy expenditure is lowered (120). 
However, the high leptin levels seen in obese subjects do not exert a 
suppressing effect on appetite due to resistance to the hormone (121). Leptin 
receptors are found in the hypothalamus, regulating metabolism, but 
receptors are expressed in several other tissues as well, and leptin has been 
shown to act in skeletal muscle to increase fatty acid oxidation (122). 
Maternal concentrations of leptin increase during pregnancy, as do fat mass. 
However, there is evidence that the increase during pregnancy is not all due 
to the increased fat mass. Leptin levels start to increase early in pregnancy 
and rapidly decline after parturition (123). The human placenta express high 
amounts of leptin mRNA, and it has been suggested that increased levels of 
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leptin during pregnancy may facilitate mobilization of maternal fat stores, 
increasing lipid substrates to the growing fetus (124). 
1.7.2 Adiponectin 
Adiponectin is the most abundant adipokine, secreted exclusively from 
adipose tissue (125).  Adiponectin has been shown to improve whole-body 
insulin sensitivity in models of diet-induced obesity (126). Adiponectin 
increase fatty acid oxidation and glucose uptake in skeletal muscle and 
adipose tissue by activation of AMP-activated protein kinase through 
adiponectin receptor 1 (127). Adiponectin also reduces glucose production 
by the liver, primarily by binding to adiponectin receptor 2 (128). It also has 
anti-inflammatory and anti-atherogenic properties (129). There is a strong 
negative correlation between plasma adiponectin concentration and fat mass 
in humans. Obesity reduces adiponectin levels, while weight loss has the 
opposite effect. Adiponectin levels are also decreased in T2D (127, 130). As 
reviewed by Briana et al (131), the influence of pregnancy on adiponectin 
levels is not clear. Some studies have shown decreased levels of adiponectin 
during pregnancy, parallel to the decrease in insulin sensitivity, while others 
have found no change during normal pregnancy. The latter is proposed as a 
protective mechanism against the decreased insulin sensitivity (131).      
1.7.3 Cytokines 
The increased fat mass in obesity has been linked to an increase in markers 
of inflammation, and TNF-α and IL-6 are the two best-studied cytokines in 
obesity. (132). However, studies have shown that this altered cytokine 
response is not primarily originating from adipocytes, but rather from the non 
fat cells of the stromal vascular fraction of adipose tissue, such as 
macrophages or leukocytes (92). TNF-α was the first cytokine to be 
suggested as a link between obesity, inflammation and insulin resistance, 
with higher expression in adipose tissue in obesity (111). TNF-α has been 
shown to impair insulin signaling in adipose tissue, and chronic treatment 
with TNF-α decreased insulin-stimulated glucose uptake in rat muscle (133, 
134). Neutralization of TNF-α has been suggested as a therapeutic target for 
treating T2D, however, improvement in insulin sensitivity during therapy 
could not be seen (135). 
As with TNF-α, most of the adipose tissue derived IL-6 originates from the 
stromal vascular fraction and approximately 1/3 of circulating levels is 
attributed to adipose tissue production (136, 137). Increased circulating 
levels of IL-6 are correlated with obesity and development of T2D (138). 
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Increased levels of TNF-α and IL-6 during pregnancy have mainly been 
attributed to placental production and maternal concentrations of these 
cytokines are increased in gestational diabetes mellitus (131, 139). However, 
knowledge of the contribution of adipose tissue in this respect is missing. 
Besides TNF-α and IL-6, there are over 100 inflammatory cytokines 
identified with both pro- and anti-inflammatory properties but their role in 
obesity-related pathogenesis is largely missing (117).  
1.7.4 Chemerin 
Chemerin is a chemoattractant adipokine, highly expressed in mature 
adipocytes, liver and placenta (140). Chemerin has been proposed as a 
potential link between obesity and T2D (141), as serum levels of chemerin 
are increased in obesity and adipose tissue secretion from tissue explants is 
higher in obese subjects as compared to normal weight subjects (141, 142). It 
has been shown that chemerin is necessary for adipocyte differentiation and 
it has been proposed that enhanced expression of chemerin in enlarged 
adipocytes acts as a physiological stimuli to promote adipogenesis. Chemerin 
release from adipocytes is also increased by stimulation of TNF-α (142).  
1.7.5 Dipeptidyl peptidase 4 
DPP4 is an adipokine that has been implicated in the development of co-
morbidities associated with obesity (143). Serum levels are increased in 
obesity and reduced following weight loss and there is a strong relationship 
between serum concentrations and adipocyte size (143). In mice lacking 
DPP4, insulin secretion was increased and glucose tolerance was improved 
(144), however the effects of DPP4 on β-cell function remains unclear (145).  
1.7.6 Omentin 
Omentin is proposed to be an adipokine with anti-inflammatory and insulin-
sensitizing properties. It is a depot-specific adipokine, almost exclusively 
expressed in, and released from visceral adipose tissue (146). Omentin is 
expressed by the stromal vascular fraction of adipose tissue, rather than by 
the adipocytes and omentin gene expression and circulating levels are 
reduced in obesity (147). Circulating levels are negatively correlated to a 
number of metabolic risk factors, such as waist circumference, glucose 
intolerance and dyslipidemia (148). Omentin has been shown to stimulate 
glucose uptake in adipocytes cultured in vitro (146) and weight reduction in 
obese subjects increased circulating levels of omentin (149). 
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1.7.7 Adipocyte fatty acid-binding protein 
Adipocyte fatty acid-binding protein (AFABP) is an adipokine that also has 
been described as being associated with development of insulin resistance, 
T2D and cardiovascular disease. Serum levels are increased in overweight 
and obese subjects and there is a positive correlation between AFABP levels 
and waist circumference (150). In a knockout model, mice lacking AFABP 
did not develop insulin resistance and diabetes, although weight gain was 
similar to control-animals (151). It has been suggested that high levels of 
circulating AFABP induce insulin resistance due to increased hepatic glucose 
production (152). Besides the association to T2D, increased circulating levels 
of AFABP has also been shown in gestational diabetes mellitus (153). 
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2 AIM 
The overall aim of this thesis was to increase our knowledge of human 
adipose tissue morphology and function and its role in pathogenesis of 
metabolic disease with focus on GDM and T2D. 
2.1 Specific aims 
Paper I 
§ To determine the effect of commonly used bovine, and human, 
albumin preparations on cytokine release from adipose tissue in 
vitro. 
§ To establish a system for adipose tissue short-term incubation 
minimizing induction of cytokine release. 
§ To compare the release of adipokines, implicated in inflammation 
and insulin resistance, from subcutaneous and visceral adipose tissue. 
 
Paper II 
§ To characterize adipose tissue morphology and function in normal 
weight and obese women longitudinally during pregnancy. 
§ To identify adipose tissue-related factors associated with gestational 
insulin resistance. 
 
Paper III 
§ To characterize adipose tissue morphology and function, in relation 
to glucose metabolism, in women six years after gestational diabetes 
mellitus. 
§ To identify adipose tissue-related factors associated with impaired 
glucose metabolism and insulin resistance at follow-up 
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3 SUBJECTS AND METHODS 
3.1 Subjects 
3.1.1 Paper I 
Adipose tissue biopsies were obtained from 6 men and 11 women 
undergoing elective abdominal surgery at Sahlgrenska University Hospital. 
To evaluate the effects of different albumin preparations on cytokine release 
from adipose tissue in vitro, subcutaneous adipose tissue from 6 patients was 
studied (abdominoplasty in 5, hysterectomy in 1). Paired subcutaneous and 
visceral adipose tissue biopsies were obtained from 11 patients (Roux-en-Y 
gastric by-pass in 9 and cholecystectomy in 2) to compare adipokine release 
from subcutaneous and visceral adipose tissue. Patients were recruited to the 
study at the time of admittance to the hospital prior to surgery together with 
collection of information on age, height, weight and medical history. No 
subjects with malignant disease were included. 
3.1.2 Paper II 
Normal weight and obese pregnant women in the Pregnancy, Obesity, 
Nutrition and Child Health study (PONCH) were included. The PONCH-
study is a longitudinal study focused on health in normal weight and obese 
pregnant women and their children. The study scheduled three study visits at 
Sahlgrenska University Hospital during pregnancy (first visit in trimester 1, 
gestational weeks 8-12, second visit in trimester 2, weeks 24-26, and third 
visit in trimester 3, weeks 35-37). All three visits included blood- and urine 
sampling, determination of body composition, anthropometry and food- and 
physical activity questionnaires. The women and children were also followed 
postpartum. Inclusion criteria were BMI 18.5-24.9 or >30 kg/m2 and >20 
years of age. Exclusion criteria were non-European descent, vegan diet, 
diabetes, use of neuroleptic drugs and twin pregnancy. Women who 
consented to an optional adipose tissue biopsy at study visits in trimester 1 
and 3 were eligible for this study. In total, 22 normal weight women and 11 
obese women completed both study visits including adipose tissue sampling. 
Women were recruited through maternity care, by advertisement on a 
pregnancy-related website and by postings on public billboards. At inclusion, 
normal weight and obese women were randomized to either dietary 
counseling groups or control groups. Normal weight and obese control 
groups did not receive any dietary counseling in addition to the advice given 
Henrik Svensson 
17 
to all women at maternity care centers during pregnancy. The dietary 
counseling groups were given advise by a dietitian during pregnancy to 
increase adherence to the Nordic Nutrition Recommendations (154). The 
obese dietary counseling group was also given advice to reduce caloric intake 
20% of their calculated need during pregnancy. Since the interventions had 
no significant effect on reported energy intake, body composition or any 
other variable, compared with corresponding control groups, the normal 
weight and obese groups were separately pooled.  
3.1.3 Paper III 
Participants were recruited from a larger cohort of women, all diagnosed 
with gestational diabetes mellitus in Gothenburg between 2005 and 2007. 
Between five to six years after index pregnancy the women were contacted 
by telephone and offered to participate in a follow-up study and those 
interested received further information by mail. Two study visits were 
scheduled in the follow-up study. The first visit included an OGTT, 
anthropometry and blood sampling. The second visit included an optional 
adipose tissue biopsy and determination of body composition. Women who 
consented to adipose tissue sampling were included in this study. Women 
who were pregnant at the time for follow-up were not eligible to participate, 
and further exclusion criteria were diagnosis of type 1 and type 2 diabetes or 
other endocrine diseases that affect adipose tissue, malignancies, use of 
neuroleptic drugs, and gastric bypass surgery between the index pregnancy 
and follow-up. In total, 39 women were included in the study. 
3.2 Ethics 
All participants received information about the studies and gave oral and 
written consent prior to inclusion. All studies were conducted in accordance 
with the principles of the Declaration of Helsinki and approved by the 
Regional Ethical Review Board in Gothenburg. 
3.3 Methods 
3.3.1 Adipose tissue sampling 
In paper I surgical adipose tissue biopsies were obtained from participants at 
the beginning of the surgical procedure. Abdominal subcutaneous adipose 
tissue was sampled after the initial incision and visceral adipose tissue 
(greater omentum) was collected when the surgeon reached the peritoneal 
cavity. When subcutaneous adipose tissue was collected from patients 
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undergoing abdominoplasty, adipose tissue was collected when the larger 
piece of tissue had been removed from the donor. The tissue was 
immediately placed in Medium 199 (Invitrogen, Carlsbad, CA) and 
transported to the lab. 
In papers II and III subcutaneous adipose tissue biopsies was obtained by 
needle aspiration. In the non-pregnant women in study III adipose tissue was 
sampled from the umbilical region, at a point one-third of the distance from 
the superior anterior iliac spine to the umbilicus. In pregnant women, 
especially late in gestation, a biopsy in this region is hard to acquire. The 
biopsy was therefore obtained more laterally on the abdomen, in the 
umbilico-lumbar region, at the level of the umbilicus. After superficial 
injection of local anesthetic, a needle attached to a syringe was inserted into 
the subcutaneous adipose tissue. A negative pressure was applied in the 
syringe and the needle was moved back and forth in the tissue allowing for 
numerous small shreds of adipose tissue to be collected in the syringe. The 
tissue was rinsed with saline, weighed and prepared according to the study 
protocols. All handling of tissue was performed under aseptic conditions. 
3.3.2 Anthropometry and body composition 
In paper I body weight and height was measured according to standard 
clinical procedure in the morning before surgery (paired biopsies of 
subcutaneous and visceral adipose tissue) or reported by the patients 
(subcutaneous adipose tissue).  
In papers II and III waist- and hip circumferences, and height, were measured 
by standard protocols and body composition was determined using Bod Pod 
(Cosmed, Rome, Italy). The Bod Pod system is based on air displacement 
plethysmography and measures body volume and body mass (a calibrated 
scale connected to the system) so that total body density can be calculated 
(155). By using the equation of Siri (156), based on the two-component 
model and the densities of fat mass (0.900 kg/l) and fat free mass (1.100 
kg/l), body fat mass and fat free mass can be estimated. The Bod Pod has 
been validated in a wide range of subjects, normal weight to obese, as well as 
different ethnic groups and in children (157). The use of air-displacement 
plethysmography has also been validated for use during pregnancy (158). 
However, as pregnancy progress the hydration of fat free mass increases, 
leading to a progressive over-estimation of fat mass with advancing 
gestational age if the density of fat free mass is not corrected for. By 
adjusting the density of fat free mass to compensate for the increased water 
content of the tissue this effect can be minimized (159).  
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3.3.3 Adipocyte size determination 
Adipocyte size can be measured using a variety of methods and each method 
has its advantages and disadvantages. One commonly used technique is 
manual measurements of freshly isolated adipocytes in a suspension by using 
a microscope and an ocular with a calibrated scale. With this method about 
one to a few hundred cells are usually measured. The method is time 
consuming and there may be a selection-bias. Further, analysis must be 
performed immediately after collagenase digestion of the tissue to avoid 
changes in cell morphology (160). Adipocyte size can also be assessed using 
conventional histologic preparations for microscopic measurements. This 
method allows for more adipocytes to be analyzed, but adipocytes may be 
distorted during preparation of histological sections impairing interpretation 
(161). Another technique is automatic sizing of osmium tetroxide-fixed 
adipocytes allowing for a large number of cells to be analyzed (161, 162). 
However, this method involves toxic substances and may potentially fix and 
analyze cell debris from ruptured cells (88). Also, fixation of the cells with 
osmium tetroxide may cause cell-swelling (162). 
Computerized analysis of photomicrographs of adipocytes, isolated by 
collagenase digestion, allows for a large number of adipocytes to be 
measured rapidly (163). Further, only image acquisition has to be performed 
on fresh cells and analysis may be carried out at a later stage. The digital 
images and results of the computerized analysis can be stored for future 
reference. Analysis of large numbers of adipocytes allows for more detailed 
size distribution curves and stratification of adipocytes in different size 
ranges. One possible limitation of methods using collagenase digestion is that 
potentially fragile large adipocytes may rupture during preparation. If 
breakage is profound, adipocyte size may be underestimated. By avoiding 
centrifugation of the cell suspension, using siliconized glassware, and 
adequate amounts of collagenase, cell breakage can probably be minimized. 
Cell breakage causes lipid droplets that must be manually excluded in the 
analysis. Lipid droplets are usually easy to distinguish from adipocytes in the 
images but if somewhat out of focus lipid droplets may be difficult to 
recognize, particularly if they are small. 
In these studies adipocytes were isolated by collagenase digestion using, a 
water bath with gentle orbital shaking at 37°C. Undigested stroma was 
separated from the adipocytes by filtration through a nylon mesh. Adipocytes 
were allowed to float and the medium, including other cell types, was gently 
removed and replaced with fresh medium to wash the adipocytes free from 
collagenase and non-adipocytes. This procedure was performed three times. 
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The cell suspension was placed on a siliconized glass slide, immediately 
covered with a coverslip, and transferred to the microscope. By means of a 
computerized macro 12 visual fields (5X objective) were photographed. The 
same macro was used in analysis of the images (Leica QWin V3, Leica 
microsystems, Wetzlar, Germany). The area within contours meeting criteria 
for roundness and smoothness was determined and the corresponding 
diameter was calculated. Microspheres with a uniform diameter of 98 µm 
served as reference (Dynal, Invitrogen Corporation, Oslo, Norway). In paper 
I, mean adipocyte volume was calculated using Goldrick’s formula (πd 
[3(SD)2 + d2]/6), where d is the mean adipocyte diameter and SD is the 
adipocyte diameter standard deviation (164). In papers II and III, mean 
adipocyte volume was determined as the average of all adipocyte volumes.  
3.3.4 Basal lipolysis 
Lipolysis is the process of hydrolysis of triglycerides in the adipocyte to free 
fatty acids and glycerol upon metabolic demand. The surface of the lipid 
droplet contains enzymes that respond to hormonal stimulation when fuel is 
needed. Three major lipases account for mobilization of triglycerides in the 
lipid droplet; adipose triglyceride lipase hydrolyzes the first fatty acid from 
the triglyceride, hormone-sensitive lipase hydrolyzes diacylglycerol to 
monoacylglycerol, and monoacylglycerol lipase removes the last free fatty 
acid, leaving the free fatty acids and one molecule of glycerol (165). In paper 
II and III basal lipolysis, i.e. the lipolytic activity measured without 
stimulating or inhibiting agents, was assessed by incubating adipocytes, 
isolated by collagenase digestion, in minimal essential medium for two 
hours. Following incubation, cells and media was centrifuged through 
silicone oil to remove cells, and glycerol released into the medium was taken 
as an index of basal lipolysis.  
3.3.5 Immunohistochemistry 
Immunohistochemistry was used to determine the density of macrophages 
(papers I-III), mast cells (papers II-III) and vessels (papers II-III) in adipose 
tissue. A part of each biopsy was placed in phosphate-buffered formalin and 
subsequently processed for immunohistochemical staining according to 
standard protocols including dehydration, embedding in paraffin and 
sectioning at 5 µm. Following rehydration, the slides were subjected to high 
temperature antigen retrieval, blocking of unspecific epitopes and incubation 
with primary antibodies over night. A secondary antibody and chromogen 
was added, followed by rapid dehydration and mounting. Glass slides were 
digitized prior to computerized analysis.  
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Quantification of immunoreactive cells in tissue is traditionally performed by 
manual counting of cells with positive signal in a slide using a microscope or 
a photomicrograph of the slide. In recent years, digital pathology has 
developed and software for automatic counting is available. In paper I 
macrophage density was determined manually on digitized tissue slides and 
the origin of the tissue unknown to the observer. To quantify macrophages, 
mast cells and vessels in paper II and III, the software Tissue Studio (version 
3.6.1, Definiens, Munich, Germany) was used. In order to quantify 
immunoreactive signals using this software, a runtime had to be setup and 
tested to fit the properties of the tissue studied. The software has an intuitive 
self-learning feature, where the operator informs the software of all the 
different types of tissue in the slides, what to include in analysis and what to 
exclude. After self-learning, batch analysis can be performed. A challenge is 
the adipose tissue itself. During adipose tissue processing, lipid in the 
adipocytes is washed out leaving them empty. As a result, the tissue appears 
pale and the software may have difficulties differentiating tissue from 
background. Extra precautions and fine-tuning of settings had to be carried 
out prior to analysis. The number of mast cells and macrophages was 
normalized for surface area by the software. Adipocyte size could potentially 
affect the results why immune cell density was also expressed per 103 
adipocytes using the adipocyte area distribution curve. However, the way of 
normalization did not influence the results.  
In paper II, vessel density was expressed as the ratio of the positive signal 
area to the total specimen area. In paper III, vessel density was expressed as 
immunoreactive area per adipocyte. 
3.3.6 In vitro release of adipokines 
Adipokines may be quantified in a number of ways and each method has its 
advantages and disadvantages. The purpose of the analysis may be guiding in 
the choice of sample type and analytical method. Blood sampling followed 
by biochemical analysis is used extensively. An ELISA for example is 
relatively easy to perform and usually rather inexpensive. However, no 
conclusions can be drawn regarding the adipose tissue contribution to 
measured levels. Some adipokines, like leptin and adiponectin, are almost 
exclusively secreted from adipocytes while others, like cytokines, may 
originate from other organs, tissues and cells as well. Gene expression 
analysis is a method widely used to study mRNA levels of adipokines in 
specific cells or tissues. Expression analysis may for example be performed 
in whole adipose tissue, isolated adipocytes or the stromal vascular fraction. 
The analysis can be applied for a specific gene or large scale but mRNA 
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expression may not always reflect corresponding expression at the protein 
level or protein release. Subcutaneous microdialysis is a technique that may 
be used for determination of adipokine concentrations in the extra cellular 
space. A fluid is allowed to diffuse through the tissue in vivo and then 
collected for subsequent analysis of adipokine content. Microdialysis 
concentrations reflect the secretion of adipokines from the tissue but the 
technique is best suited for smaller studies as it is time consuming, both for 
the subject and the operator. Further, microdialysis can not be used to study 
adipokine release from visceral adipose tissue. Analysis of adipokines 
released in vitro from adipose tissue explants or isolated adipocytes is 
another commonly used technique. Using this approach, adipokine release 
specifically from adipose tissue or adipocytes is assessed, but the method is 
more invasive, compared with blood sampling, as an adipose tissue biopsy 
must be obtained. Also, in vitro “artifacts” have to be considered. In paper I, 
supplementation of incubation media with different albumin preparations 
was evaluated. Albumin is usually added to the incubation medium as a fatty 
acid acceptor. High concentrations of free fatty acids may otherwise exert 
toxic effects on the tissue during incubation. However, bovine serum 
albumin (BSA) has been reported to induce cytokine release from adipose 
tissue in vitro (166). This effect may be depending on endotoxin in the 
albumin preparations although cytokine induction has also been observed 
with endotoxin-free BSA (167). Species differences may thus underlie the 
reaction. As shown in paper I, human serum albumin did not induce cytokine 
release, as compared with no addition of albumin. Human serum albumin 
was therefore added to media used in papers I-III to study adipokine release 
in vitro. Adipose tissue explants of 5-15 mg each, in total about 250 mg, 
were placed in 10 ml Medium 199 (Invitrogen) supplemented with 1% HSA 
and incubated at 37°C for maximum 24 hours. In paper I, one incubation tube 
was prepared for each specific incubation period (2, 4, 6, 8, 24 hours), while 
in paper II and III, due to limited amount of tissue, the tissue was first 
incubated for four hours, medium was collected and replaced with fresh 10 
ml of medium, and the incubation continued for another 20 hours. Media 
were stored at -80 °C until analysis. 
 
3.3.7 Assessment of insulin sensitivity and 
glucose tolerance 
There are several methods to estimate whole-body insulin sensitivity based 
on the relationship between glucose and insulin. The gold standard method is 
considered to be the euglycemic-hyperinsulinemic clamp during which the 
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amount of glucose metabolized per unit of body weight is measured during 
infusion of a predetermined amount if insulin. Plasma glucose levels are 
maintained by simultaneous infusion of glucose. However, this technique is 
time consuming and invasive why several surrogate measures for insulin 
sensitivity has been adopted. One widely used index for insulin sensitivity, 
based on the feedback loop of fasting insulin and fasting glucose, is the 
homeostasis model assessment of insulin resistance (HOMA-IR) (paper II 
and III). HOMA-IR is calculated by multiplying fasting insulin (mU/liter) 
and fasting glucose (mmol/liter), divided by 22.5 (168). HOMA-IR correlates 
well with insulin sensitivity as determined with the euglycemic 
hyperinsulinemic clamp technique, evaluated in the general population 
(R=0.88, P<0.0001)(168) as well as during pregnancy (R=0.73, P<0.0001) 
(169). 
OGTT is widely used as a diagnostic tool for T2D and GDM. Glucose levels 
are measured in the fasted state followed by ingestion of a predefined amount 
of glucose (in Sweden most often a solution containing 75g glucose). Two 
hours after ingestion of the glucose load a new measurement of plasma 
glucose is made and the response to the glucose load can be interpreted. 
Based on the levels of fasting glucose and 2 h glucose levels NGT, IFG, IGT 
and T2D are defined. To assess glucose tolerance at follow-up in paper III all 
participants underwent a 75g OGTT and based on the results of fasting 
and/or 2 h plasma glucose women were classified as NGT, IFG, IGT or T2D. 
3.3.8 Biochemical assays 
All plasma/serum/medium concentrations of analytes were determined after 
an overnight fast. In paper I a multiplex immunoassay, based on electro-
chemiluminiscens, was used to simultaneously analyze concentrations of 
nine cytokines in conditioned media (Human pro-Inflammatory 9-Plex Ultra-
Sensitive Kit, Meso Scale Discovery, Gaithersburg, MD). In papers I-III 
enzyme-linked immunosorbent assays (ELISA) was used to measure 
concentrations of adipokines in serum and conditioned media. In principle, 
ELISA is a technique used to detect and quantify a biological substance by 
first binding it to a capture antibody at the surface of the well and then 
adding a detection antibody that binds to another site of the molecule of 
interest. This antibody is linked to an enzyme, which in turn is incubated in 
the presence of substrate to produce a measurable product, indicated by a 
color change that is in proportion to the concentration of the molecule 
analyzed. Results are often obtained through reading the absorbance of the 
sample and comparing it to a series of samples with known concentrations, 
thus making a standard curve. All blood and medium samples were analyzed 
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at the Clinical Chemistry Laboratory, Sahlgrenska University Hospital, 
accredited in accordance with the International Standard ISO 15189:2007, 
with the exception of HbA1c in paper III, which was analyzed using a point 
of care analyzer. 
3.3.9 Statistical analyses 
Statistical analyses were performed using SPSS statistical software version 
18 for Microsoft Windows (paper I) and version 21 for MacOS X (papers II 
and III) (SPSS inc, Chicago IL). Results are expressed as mean ± standard 
error of the mean (SEM) in paper I, and mean ± standard deviation (SD) in 
paper II and III. P<0.05 was considered significant. 
Paper I 
Values were logarithm-transformed to stabilize variances. To evaluate the 
effect of different albumin preparations on cytokine release from adipose 
tissue, using four different media at five time points, three-way analysis of 
variance was used, with “subject” as fixed factor, followed by paired t-tests 
and Bonferroni correction. The influence of supplementation with 0.1% 
albumin was assessed by two-way analysis of variance. A similar approach 
as above was used to assess differences in cytokine release from 
subcutaneous and visceral adipose tissue over time using a three-way 
analysis of variance, but instead of different media there were two different 
depots. Differences in adiponectin release in obese and non-obese subjects 
were evaluated using a split-plot design with subjects as main plots 
(obese/non-obese) and incubation times as subplots. The split plot design 
originates in agricultural science where the yield using different 
combinations of seeds and fertilizers was evaluated, hence the name split 
plot. T-test was used to compare macrophage density and adipocyte size in 
subcutaneous and visceral adipose tissue, and Pearson correlation was used 
to evaluate the relationship between adipocyte size and adiponectin release.  
Paper II 
Comparisons between trimester 1 and 3 within groups were made using the 
related-samples Wilcoxon signed-rank test. Comparisons of groups early and 
late in gestation, as well as comparison of change between groups during 
pregnancy were assessed using Mann-Whitney U test. Spearman’s rank-
correlation test was used to evaluate associations between adipocyte size 
early in pregnancy and the change in the proportion of adipocytes <100 µm 
during pregnancy, and between the proportion of adipocytes >150 µm and 
circulating adipokines in trimester 3. Variables, significantly correlated to 
HOMA-IR as assessed by Spearman’s rank-correlation test, were introduced 
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as independent variables in multivariable linear regression to identify 
determinants of insulin sensitivity early and late in gestation.  
Paper III 
Women with NGT and IGM were compared using Mann-Whitney U test for 
continuous variables. Fishers exact test was used to compare variables with 
two categories and chi-2 test was used to compare categorical variables with 
more than two categories. Multivariable linear regression was used to 
identify determinants of HOMA-IR. Independent variables were selected by 
Spearman correlation as in paper II. By using multivariable logistic 
regression and dichotomizing the women as NGT or IGM the probability of 
having impaired glucose metabolism could be determined. Adipose tissue-
related variables were included as independent variables in this analysis. 
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4 RESULTS AND DISCUSSION 
4.1 Paper I 
In this study our aim was to develop an in vitro system reflecting the release 
of adipokines, including cytokines, from human adipose tissue in vivo. The 
system was subsequently used to compare the release of a number of 
adipokines, implicated in insulin resistance and inflammation, from 
subcutaneous and visceral human adipose tissue.  
4.1.1 In vitro effects of albumin 
Subcutaneous adipose tissue was incubated for 2, 4, 6, 8 and 24 hours in 
media supplemented with 1% BSA Fraction V, 1% BSA Essential Fatty Acid 
Free, 1% HSA, or no albumin. Medium concentrations of nine cytokines 
were measured using a multiplex immunoassay. Over 24 hours of incubation, 
levels of cytokines were higher in both media containing BSA than in media 
with HSA or no albumin. Also, supplementation of media with 0.1% BSA 
induced cytokine release. Release of adiponectin was not affected by BSA.  
Higher levels of endotoxin in media supplemented with BSA may, at least 
partly, explain the increased release of cytokines. However, the stimulatory 
effect of BSA on cytokine release has also been observed in the absence of 
endotoxin contamination suggesting other immunomodulatory effects of 
BSA (167). Despite marginally higher endotoxin levels in medium with HSA 
as compared with medium without albumin, cytokine concentrations were 
similar in medium with HSA and medium without albumin. Thus, HSA did 
not influence the release of cytokines.  
In a short-term, dilute system like this, with a high ratio of media to tissue, 
supplementation of the medium with albumin may not be necessary. In our 
final protocol, 1% HSA was added to the medium as a precaution due to the 
expected beneficial effects of albumin in stabilizing medium pH and binding 
free fatty acids released from the tissue during incubation. High 
concentrations of free fatty acids may exert toxic effects on the tissue (170). 
Thus, we conclude that BSA should be avoided in media for human 
cell/tissue incubation since it seems to have intrinsic effects on cytokine 
release. 
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4.1.2 The in vitro system 
Since adiponectin is an adipocyte-specific adipokine, circulating levels of 
adiponectin reflect release from adipose tissue. Previous studies have 
reported decreased circulating adiponectin levels in obesity (171-173). In 
order to study if this difference between obese and non-obese adipose tissue 
was reflected in vitro, using our system, subcutaneous adipose tissue from 
five obese and five non-obese subjects was incubated according to our final 
protocol for 2, 4, 6, 8, and 24 hours. Adiponectin levels in conditioned media 
were analyzed by ELISA. Adiponectin release was higher in adipose tissue 
from non-obese subjects than from obese subjects in line with previous 
findings (171-173). There was also a negative correlation between 
adiponectin release from subcutaneous adipose tissue in vitro and adipocyte 
size at 4 h (r= -0.85, P<0.05, n=7) and 24 h  (r= -0.84, P<0.05, n=7), also 
consistent with previous studies on circulating levels of adiponectin (77, 78). 
Therefore, in this respect the system seems to reflect the in vivo situation. 
In line with the approach above, we chose to study omentin release in vitro 
since the expression of omentin mRNA has been reported to be markedly 
lower in subcutaneous than in visceral adipose tissue (146, 174). 
Subcutaneous and visceral adipose tissue from 11 subjects were incubated 
according to our standard protocol. Omentin was almost exclusively released 
from visceral adipose tissue, again supporting the conclusion that the release 
of adipokines in our system reflect in vivo release. 
During the 24-hour incubation period, increasing amounts of adipokines 
accumulated in the medium and release was linear for 2-6 h. Previously, 
pieces of adipose tissue have been incubated under similar conditions, for 
several days, with maintained viability i. e. morphology and hormonal 
responsiveness (175). However, all in vitro systems have limitations. The 
tissue is subjected to different stressors during handling and incubation. Also, 
adipokine release in vivo is regulated through different mechanisms (116). 
Measured concentrations in vitro may be due to passive leakage, consecutive 
release, or both, and may also be stimulated or inhibited by different factors.  
Taken together, under the conditions used adipokines accumulate in the 
medium over 24 h. The system reflects differences in adipose tissue 
adipokine release observed in vivo, depending on BMI and adipocyte size, as 
well as differences depending on gene expression levels. The results suggest 
that the system is suitable for further analyses of the adipose tissue secretome 
and differences between depots.  
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4.1.3 Depot-dependent release of adipokines  
Paired subcutaneous and visceral adipose tissue biopsies were obtained from 
11 subjects and incubated as described above using 1% HSA. Cytokines 
were analyzed in conditioned media by multiplex immunoassay. All nine 
cytokines, except IL-6, were more abundantly released from visceral than 
subcutaneous adipose tissue. 
Adiponectin, chemerin, IL-6 and DPP4, all implicated in insulin resistance 
(30, 127, 142, 143), were also analyzed by ELISA in media from paired 
biopsies of subcutaneous and visceral adipose tissue. Adiponectin release 
was higher in subcutaneous adipose tissue. Previous studies regarding depot-
dependent release of adiponectin are inconsistent, reporting higher release 
from subcutaneous adipose tissue explants (176, 177) and a tendency of 
higher secretion from omental than subcutaneous adipocytes (178). Gene 
expression analysis has shown lower expression of adiponectin mRNA in 
visceral vs subcutaneous fat, both in normal weight and obese subjects, 
consistent with our findings (179, 180).   
Release of IL-6 was similar between the two adipose tissue depots. Previous 
reports have demonstrated higher secretion of IL-6 from visceral adipose 
tissue (91, 181, 182). Release of cytokines from adipose tissue is mainly due 
to cells of the stromal vascular fraction (91, 181, 182). In this study, visceral 
adipose tissue had a higher macrophage density consistent with more 
abundant release of IL-6 from the visceral depot in numerical values. A 
limited number of observations and large variations between subjects may 
explain the discrepancies. 
Both chemerin and DPP4 were more abundantly released in visceral adipose 
tissue. Depot-dependent release of chemerin has not previously been 
investigated, but in obese subjects circulating levels were correlated with 
BMI and measures of central adiposity (WHR, waist circumference and 
visceral adipose tissue mass) suggesting a link between chemerin levels and 
visceral adipose tissue (183). The expression of chemerin mRNA was also 
higher in the omentum compared with subcutaneous adipose tissue in 
patients with T2D (184). Serum levels of DPP4 are increased in obesity and 
DPP4 has been proposed to be a marker of the metabolic syndrome and to 
impair insulin sensitivity (143). Previous studies, using western blot, showed 
higher DPP4 in visceral than subcutaneous adipose tissue (143), consistent 
with our finding.  
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In conclusion, this study shows that there are functional differences between 
subcutaneous and visceral adipose tissue, in terms of adipokine release, 
consistent with clinical observations. The developed in vitro system, 
including HSA, may be used to further explore the link between regional fat 
accumulation and metabolic disease. 
4.2 Paper II 
During pregnancy a physiologically normal insulin resistance is established 
(185). In this study our aim was to characterize adipose tissue morphology 
and function longitudinally during pregnancy and identify adipose tissue-
related factors associated with gestational insulin resistance. Twenty two 
normal weight and 11 obese women were recruited early in pregnancy and 
consented to undergo adipose tissue sampling in trimester one and three 
together with assessment of body composition and blood sampling. At 
inclusion, subjects were randomized to either control or intervention groups 
with the main purpose to evaluate the effect of dietary counseling including 
energy restriction in obese pregnant women. However, as there were no 
differences between control and intervention groups regarding reported 
energy intake, body composition or metabolic status in trimester one or 
during pregnancy, the control and intervention groups were pooled. 
4.2.1 Early pregnancy characteristics in normal 
weight and obese women 
The mean BMI was 22.3 kg/m2 (range 19.1-23.9) in the normal weight group 
and 35.3 kg/m2 (range 30.4-41.8) in the obese group. Obese women had 
higher fat mass, circulating leptin, AFABP, and CRP and HOMA-IR, while 
circulating levels of adiponectin was higher in normal weight women early in 
pregnancy.  
As expected, obese women had more adipocytes and larger mean adipocyte 
volume, reflected in a lower proportion of small adipocytes (50-100 µm in 
diameter) and a higher proportion of large (100-150 µm in diameter) and 
very large adipocytes (>150 µm in diameter). Basal lipolytic activity was 
higher in the obese group. Release of IL-6, TNF-α, and adiponectin in vitro, 
and adipose tissue immune cell and vessel densities were similar in the 
groups early in pregnancy. 
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4.2.2 Changes during pregnancy in normal 
weight and obese women 
Normal weight, but not obese women increased in fat mass during pregnancy 
although there was a borderline significant increase in fat mass also in the 
obese group (P=0.050). Weight gain, and fat mass gain were similar when 
the groups were compared. Previous studies on changes of body composition 
during pregnancy are inconsistent; reporting lower (186), similar (187) or 
higher (188) accumulation of fat in obese women compared to normal weight 
women. Fat mass gain during pregnancy is tightly correlated with gestational 
weight gain (186, 188), why reported differences in fat mass gain may be 
explained by differences in gestational weight gain. In the study reporting 
lower fat mass gain in obese women (186), only obese women gaining 
weight as recommended by the Institute of Medicine (lower weight gain for 
obese than for normal weight women) were included. There may also be 
methodological considerations since assessment of body composition during 
pregnancy is a challenge. As for example, estimates of body composition 
during pregnancy using four-component models (186, 188) or two-
component models (187) are unable to distinguish maternal from fetal 
tissues. However, if the density of fat-free mass is adjusted according to 
gestational age, the two-component model can provide useful results of body 
composition also during pregnancy (158). 
HOMA-IR increased similarly in both groups during pregnancy, however, all 
women remained normoglycemic. Also, lipolytic activity increased similarly 
during pregnancy to meet the needs of the growing fetus. Circulating 
AFABP, implicated in inflammation and a suggested marker of metabolic 
disease (189), was higher in obese women both early and late in gestation but 
increased similarly during pregnancy when groups were compared. Obese 
women had higher levels of CRP in trimester one, however during pregnancy 
normal weight women increased in CRP, and in trimester three there were no 
differences between the groups. This finding is in line with previous 
observations of increased inflammatory activity in overweight and obese 
women compared with normal weight women early in pregnancy while the 
inflammatory activity was similar in the groups late in pregnancy (190). 
Expansion of adipose tissue can be achieved by enlargement (hypertrophy) 
of preexisting adipocytes or recruitment of new adipocytes from 
preadipocytes (hyperplasia) or a combination of both (83). Hypertrophy of 
adipocytes may lead to increased inflammation, dysfunctional adipose tissue 
and insulin resistance (191) while hyperplasia was suggested to be protective 
(76). During pregnancy, adipocyte size (diameter and volume) increased in 
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normal weight women, reflected in a decreased proportion of small cells and 
an increased proportion of large cells, indicating mainly enlargement of 
existing adipocytes as fat mass increased. Total adipocyte number was not 
influenced in either group during pregnancy. When groups were compared, 
mean adipocyte size decreased in the obese group during pregnancy. Also, 
the proportion of small cells increased and the proportion of large cells 
decreased, the opposite of what was seen in normal weight women. These 
findings suggest recruitment of adipocytes during pregnancy in the obese 
group (Fig 2). Adiponectin release, negatively correlated with adipocyte size 
(77, 78), was decreased in normal weight women during pregnancy, and 
comparison of the groups revealed a greater reduction in adiponectin release 
in normal weight women than in obese women, further supporting adipocyte 
recruitment in the obese group. It should be noted that there were no 
significant changes within the obese group regarding adipocyte size or 
number why conclusions regarding adipocyte recruitment in obese pregnant 
women must be drawn with caution. Adipocyte recruitment has been 
reported during pregnancy (87) and in non-pregnant women (86) and 
previous studies have also shown that impaired ability of adipose tissue to 
expand during pregnancy is associated with development of GDM (41). It 
may be speculated that potential recruitment of adipocytes in obese pregnant 
women with already large adipocytes is a mechanism protecting against 
ectopic fat deposition and even more severe insulin resistance. 
 
 
  
 
 
 
 
 
Figure 2. Images of isolated adipocytes illustrating enlargement in a 
normal weight woman gaining 5.5 kg fat (left panels), and recruitment in 
an obese woman gaining 6.9 kg fat (right panels) during pregnancy. Top 
images, trimester one and bottom images, trimester three, respectively. 
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4.2.3 Factors affecting insulin resistance during 
pregnancy 
Stepwise multivariable linear regression analyses were performed with 
HOMA-IR in trimester one and three as dependent variables. Variables 
significantly correlated with HOMA-IR in the corresponding trimester were 
introduced as independent variables. A complete data set was available for 
31 women in each trimester (data on lipolysis and HOMA-IR were missing 
in one woman each in trimester one; fat mass and HOMA-IR were missing in 
one woman each in trimester three). In trimester one, weight, basal lipolytic 
activity and circulating levels of leptin together explained 88.5% of the 
variance in HOMA and weight was the variable most strongly associated 
with insulin resistance. In trimester three body fat mass and the proportion of 
very large adipocytes (>150 µm) explained 75.1% of the variance in HOMA-
IR and fat mass was the variable most strongly associated to insulin 
resistance late in gestation. This is in line with previous observations that fat 
mass has a significant impact on gestational insulin resistance (192). The 
results also suggest that the regulation of insulin sensitivity varies during 
pregnancy. It would have been interesting to include the insulin desensitizing 
placental hormones, mainly placental growth hormone, in the trimester 3 
regression as well (193).  
4.3 Paper III 
It is well established that women with a history of GDM have an increased 
risk of T2D later in life (27). To study risk factors in this pathogenesis, all 
women who were diagnosed with GDM in Gothenburg between 2005 and 
2007 were invited to participate in a follow-up study. At follow-up, the 
women underwent OGTT, blood sampling, and assessment of body 
composition. Women who consented to an optional adipose tissue biopsy 
were eligible for the present study. Our aim was to identify adipose tissue-
related factors, associated with IGM and insulin resistance at follow-up, that 
may contribute to progression to T2D in this group of women. 
Characteristics related to the index pregnancy were collected from medical 
records. 
Thirty nine women were included and based on the results of the OGTT, 
using the 1999 WHO criteria (20), NGT was identified in 31, IFG in one, 
IGT in three, combined IFG/IGT in two, and two women were identified 
with undiagnosed T2D. IFG, IGT and T2D were together denominated IGM.   
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4.3.1 Index pregnancy characteristics 
Women who at follow-up had developed IGM weighed more and had higher 
BMI early in index pregnancy. Having high pre-gravid BMI has been 
reported as a risk factor for progression to T2D after GDM (194), in line with 
these results. Other factors that have been suggested to influence the risk for 
progression to T2D after GDM include age, family history of diabetes, 
parity, previous GDM, gestational weight gain, insulin treatment during 
pregnancy, early GDM diagnosis and ethnicity (195-199). However, no 
differences were seen between the NGT and the IGM groups regarding these 
variables in the present study. The limited number of subjects (8) in the 
IGM-group should be noted though.  
4.3.2 Follow-up characteristics 
At follow-up, women with IGM had higher BMI, weighed more, and had 
gained more weight since index pregnancy than women with NGT. These 
factors have previously been reported to be associated with progression to 
T2D after GDM (200, 201). Also, women with IGM had greater fat mass, 
reflected in higher levels of circulating leptin, and higher indices of 
abdominal fat distribution. As expected, the IGM-group had higher HOMA-
IR and HbA1c consistent with the well established link between fat mass, 
especially abdominal fat, and T2D (46-50). Further, circulating AFABP was 
increased in women with IGM. 
Total adipocyte number did not differ between the groups but women with 
IGM had larger adipocytes than women with NGT, reflected in a lower 
proportion of small cells and a higher proportion of large and very large cells 
in women with IGM. Larger fat cells were expected in the IGM group given 
the higher BMI and greater fat mass in these women. Enlarged adipocytes 
have been suggested to participate in development of metabolic disorders, 
however, the mechanisms are not completely understood. Large adipocytes 
have an increased production and release of inflammatory mediators, 
contributing to the low-grade inflammation as seen in obesity and metabolic 
disorders (76). Further, large adipocytes are less sensitive to the anti-lipolytic 
actions of insulin, leading to increased levels of circulating free fatty acids, 
and the limited capacity for further lipid storage may result in ectopic lipid 
storage (191). The proportions of large adipocytes were positively correlated 
with leptin, AFABP, CRP, and mast cell density and negatively with 
adiponectin, while the opposite was observed for the small population of 
adipocytes. Adipose tissue from women with IGM also had higher release of 
TNF-α in vitro and higher mast cell density, both implicated in development 
of metabolic disease (104, 202). Taken together, these findings confirm the 
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close connection between excess fat mass, central fat distribution, metabolic 
disturbances and signs of inflammation in adipose tissue.   
4.3.3 Multivariable regressions 
Stepwise multivariable logistic regression was performed to determine risk 
factors of belonging to the IGM group, while stepwise multivariable linear 
regression was performed to investigate determinants of insulin resistance at 
follow-up as determined by HOMA-IR. 
Multivariable logistic regression 
IGM was defined as the dichotomous dependent variable and all adipose 
tissue-related variables were introduced as independent variables. All 39 
women were included in the final analysis. BMI at follow-up was associated 
with increased risk of belonging to the IGM group. Including the index 
pregnancy BMI did not change the outcome. As seen in Fig 3, the predicted 
probability of belonging to the IGM-group increased with increasing BMI in 
a non-linear fashion. The increased risk, per unit of increase in BMI, was 
lower in the lower BMI-range, whereas in the higher BMI-range, the 
probability of belonging to the IGM-group increased drastically with 
increasing BMI. By close monitoring of these women after parturition, 
especially the women in the high BMI-range, and by giving them support to 
limit weight gain, or loose weight, after pregnancy the women´s risk of 
developing IGM/T2D can be reduced.  
 
 
 
 
 
 
Figure 3. Multivariable logistic regression analysis with ±IGM as dichotomous variable 
showed increased predicted probability of belonging to the IGM group with increasing BMI. 
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Multivariable linear regression 
HOMA-IR was defined as the dependent variable. Adipose tissue-related 
variables, correlated with HOMA-IR (Spearman rank correlation), were 
selected as independent variables. The final analysis included 38 participants 
(HOMA-IR could not be calculated in one woman) and revealed that waist-
to-height ratio and adipocyte volume together explained 65.4% of the 
variation in HOMA-IR. The variable most strongly associated (highest 
correlation coefficient) with insulin resistance was waist-to-height ratio, an 
index of central fat accumulation. 
Taken together, BMI and central fat accumulation at follow-up were 
identified as risk factors for T2D after GDM, in line with previous reports 
(200, 201, 203). In addition, adipocyte volume was identified, for the first 
time, as a risk factor for T2D in this group of women. BMI, waist-to-height 
ratio, and adipocyte volume are also established risk factors for development 
of T2D in the general population (52, 55, 204).  
Adjustment of the differences in BMI between the NGT and IGM groups, 
and identification of potentially remaining differences regarding adipose 
tissue morphology and function, may reveal adipose tissue-related key 
components in the pathogenesis of T2D after GDM. 
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5 CONCLUSIONS AND FUTURE 
PERSPECTIVES 
Several studies report that the release of adipokines from adipose tissue 
varies between depots, and that this depot-dependent release may explain the 
relation between regional fat accumulation and metabolic disorders. 
Incubation of adipose tissue pieces and analysis of the medium is one 
strategy to determine which adipokines are actually released from specific 
depots and to what extent. A prerequisite is that the in vitro conditions are 
selected with care, as in the present work, so that findings obtained in vitro 
reflect the in vivo situation as closely as possible. Using the developed 
system, excluding the commonly used component BSA in the medium, we 
found more abundant release of pro-inflammatory cytokines, chemerin and 
DPP4 from visceral than subcutaneous adipose tissue. The opposite was 
observed for the insulin sensitizing adipokine adiponectin. Our findings 
confirm and extend current knowledge regarding these adipokines. The 
system is suitable for further studies of the adipose tissue secretome and 
relative differences between the adipose tissue depots of the human body. 
New large-scale techniques for identification and quantification of proteins in 
solutions such as blood or medium provide exciting possibilities. 
During pregnancy a physiologically normal insulin resistance is established 
and fat mass is usually gained. Therefore, pregnancy is a unique period to 
study development of insulin resistance and the potential role of adipose 
tissue-related factors in this process. We observed opposite changes in 
adipose tissue morphology in normal weight and obese women during 
pregnancy when the groups were compared. While normal weight women 
appeared to accumulate fat in pre-existing adipocytes (which became larger), 
the obese women had signs of adipocyte recruitment (resulting in a reduced 
mean fat cell size). Further, fat mass and the proportion of very large 
adipocytes were most strongly associated with insulin resistance late in 
pregnancy. These findings suggest that not only the placenta, but also the 
adipose tissue, contribute to gestational insulin resistance. The findings are 
also interesting given the established relationship between adipocyte size and 
metabolic dysfunction. Potential to recruit adipocytes during pregnancy may 
protect obese women against even more severe insulin resistance. The signs 
of adipocyte recruitment during pregnancy in obese women may be further 
explored using the conditioned media that have been stored. Studies of the 
capacity of the media to proliferate and/or differentiate preadipocytes in vitro 
may provide valuable information. Further, longitudinal determinations of 
adipose tissue morphology in women who develop GDM are missing. An 
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interesting focus for future studies is also to identify the potential key factor 
triggering adipocyte recruitment during pregnancy, and if the change in 
adipose tissue morphology during pregnancy is related to weight loss after 
pregnancy. 
 
It is well known that women with previous GDM are at increased risk for 
T2D later in life. The exact mechanisms behind this risk are not known 
although previous studies have identified adipose tissue-related factors to be 
of importance e. g. high pre-pregnancy BMI and high follow-up BMI. We 
found that women who developed impaired glucose metabolism six years 
after GDM had higher BMI and greater fat mass as well as altered adipose 
tissue morphology and function compared with women who remained 
normal glucose tolerant. We also identified BMI, waist-to-height ratio (an 
index of central fat accumulation), and - for the first time in this group of 
women - adipocyte volume as risk factors for T2D. Adjustment of the 
differences in BMI between the NGT and IGM groups, and identification of 
potentially remaining differences regarding adipose tissue morphology and 
function, is a future approach to identify adipose tissue-related key 
components in the pathogenesis of T2D after GDM. A longitudinal study 
design with examinations and adipose tissue sampling both during GDM-
pregnancy and at follow-up would be valuable. Further, health care providers 
should take initiative to close monitoring of these women after parturition, 
especially the women in the high BMI-range or with abdominal obesity. By 
giving these women support to loose weight after pregnancy, the risk of 
developing IGM/T2D can be reduced. 
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